Title : [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].

Pub. Date : 2016 Jun

PMID : 27155924






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Nevertheless, several retrospective studies suggest a greater efficacy of oxaliplatin in mCRC with KRAS mutation. Oxaliplatin KRAS proto-oncogene, GTPase Homo sapiens